Veru Inc. Share Price

Equities

VERU

US92536C1036

Personal Products

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
1.27 USD +4.96% Intraday chart for Veru Inc. -3.05% +76.39%
Sales 2024 * 8.1M 648M Sales 2025 * 9M 720M Capitalization 186M 14.88B
Net income 2024 * -36M -2.88B Net income 2025 * -48M -3.84B EV / Sales 2024 * 23 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 20.7 x
P/E ratio 2024 *
-4.82 x
P/E ratio 2025 *
-4.16 x
Employees 189
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.96%
1 week-3.05%
Current month+81.40%
1 month+108.23%
3 months+195.28%
6 months+39.56%
Current year+76.39%
More quotes
1 week
1.21
Extreme 1.21
1.48
1 month
0.67
Extreme 0.67
1.92
Current year
0.36
Extreme 0.36
1.92
1 year
0.36
Extreme 0.36
1.92
3 years
0.36
Extreme 0.36
24.55
5 years
0.36
Extreme 0.36
24.57
10 years
0.36
Extreme 0.36
24.57
More quotes
Managers TitleAgeSince
Founder 65 01/01/71
Chief Executive Officer 63 30/10/16
Director of Finance/CFO 65 31/12/12
Members of the board TitleAgeSince
Chief Executive Officer 63 30/10/16
Director/Board Member 49 30/10/16
Director/Board Member 66 28/02/18
More insiders
Date Price Change Volume
26/04/24 1.27 +4.96% 1,282,188
25/04/24 1.21 -8.33% 2,063,064
24/04/24 1.32 +3.53% 1,552,753
23/04/24 1.275 +0.39% 2,636,035
22/04/24 1.27 -3.05% 1,409,523

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.27 USD
Average target price
3.333 USD
Spread / Average Target
+162.47%
Consensus